ArticlesFeasibility of neonatal screening for toxoplasma infection in the absence of prenatal treatment
Introduction
Infection with Toxoplasma gondii occurs worldwide.1 Fetal infection with T gondii may result in severe congenital defects like hydrocephalus, mental retardation, and retinochoroiditis, which may be present at birth or develop later in life. Early treatment is believed to prevent late-onset sequelae.2, 3, 4
The best approach to prevention and control of congenital toxoplasma infection is not clear. Some studies recommend health education alone,5 whereas in Austria and France, prenatal screening and treatment are carried out.6, 7 Studies showing the beneficial effect of prenatal screening were, however, done more than 30 years ago, when most pregnant women were immune and the incidence of infection in seronegative women was ten to 20 times higher than it is now.8, 9, 10 Since then, the seroprevalence in most countries had declined,11, 12 and the majority of pregnant women are seronegative and have a low risk of infection. The benefit of prenatal screening should therefore be balanced against the risk of side-effects from invasive diagnosis and treatment.
In this situation, neonatal screening seems an attractive and cost-effective alternative to prenatal screening or to health education alone. Neonatal-screening programmes for congenital toxoplasmosis have so far been rejected in Europe, since this approach means that infected women do not receive treatment during pregnancy. However, such screening had been used in New England, USA, for a decade.13
The study from New England showed that neonatal screening for congenital toxoplasma infection was feasible in a low-risk situation, based on analysis of toxoplasma-specific IgM antibodies eluted from the phenylketonuria (PKU) card.13 However, the study could not identify congenital infection with toxoplasma in IgM-negative neonates, and there is uncertainty about the number of toxoplasma-infected children not identified by the study.
Our study primarily aimed to find out the birth prevalence of congenital toxoplasma infection in live neonates, the maternofetal transmission rate in untreated, infected pregnancies, and the risk of clinical sequelae in children born to untreated mothers. The second aim was to assess the feasibility and acceptability of a neonatal screening programme based on detection of toxoplasma-specific IgM antibodies eluted from the PKU card.
Section snippets
Patients
Pregnant women from five counties in Denmark who gave birth to live infants were offered screening at delivery for primary toxoplasma infection during pregnancy; this population is about a third of all deliveries in Denmark. The study period was 51 months (June 1, 1992, to Aug 31, 1996), and all infants of seroconverted mothers were followed up for 12 months after birth.
Design and procedures
First-trimester serum samples (routinely taken for syphilis testing) were obtained from pregnant women betwen weeks 8 to 12 of
Results
During the 51-month study period 99 246 PKU cards from consecutive liveborn infants were received. 179 (0·18%) mothers refused to take part in the study. The first-trimester sample was missing from 9194 (9·26%) mothers, mainly because the first-trimester sample for syphilis is no longer mandatory, and their infants were excluded from the analysis. Infants from 89 873 mothers were included in the final analysis. Toxoplasma-specific IgG antibodies were detected in 24 989 of 89 873 PKU cards
Discussion
We found that there was a low risk of maternofetal transmission in women with untreated toxoplasma infection during pregnancy, and a low risk of substantial clinical signs in liveborn children with congenital toxoplasma infection. Maternofetal transmission rates for untreated pregnancies have been quoted at 15% in the first trimester, 25% in the second trimester, and 65% or more in the third trimester.8 Studies of treated women have reported lower transmission rates than these quoted rates from
References (23)
- et al.
What is known about the prevention of congenital toxoplasmosis?
Lancet
(1990) - et al.
Toxoplasma gondii antibodies in pregnant women in Stockholm in 1969, 1979, and 1987
Lancet
(1991) - et al.
Congenital toxoplasmosis: a prospective study of 4048 obstetric patients
Am J Obstet Gynecol
(1971) - et al.
Epidémiologie de la toxoplasmose: situation au niveau mondial
Schweiz Med Wochenschr
(1995) - et al.
Congenital toxoplasmosis: a long-term follow-up of 20 years
Int Ophthalmol
(1989) - et al.
Early and longitudinal evaluations of treated infants and children and untreated historical patients with congenital toxoplasmosis: the Chicago collaborative treatment trial
Clin Infect Dis
(1994) - et al.
Development of adverse sequelae in children born with subclinical congenital toxoplasma infection
Pediatrics
(1980) Prevention of toxoplasmosis: observations on follow-up experience in France
Prog Clin Biol Res
(1985)- et al.
15 years of toxoplasmosis surveillance of pregnant women in Austria: an exemplary results in the prevention of neonatal infection
Österr Krankenpflegez
(1990) - et al.
Toxoplasmosis in pregnancy and its transmission to the fetus
Bull N Y Acad Sci
(1974)
Congenital toxoplasmosis: a prospective survey in Brussels
Br J Obstet Gynaecol
Cited by (185)
Toxoplasmosis screening during pregnancy in France: Opinion of an expert panel for the CNGOF
2020, Journal of Gynecology Obstetrics and Human ReproductionHuman Toxoplasma infection
2020, Toxoplasma Gondii: The Model Apicomplexan - Perspectives and MethodsTreatment of toxoplasmosis: Current options and future perspectives
2019, Food and Waterborne ParasitologyViral, Protozoan, and Related Intracranial Infections
2018, Volpe's Neurology of the NewbornEvaluation of the Western blotting method for the diagnosis of congenital toxoplasmosis
2016, Jornal de PediatriaCitation Excerpt :All children are considered suspect whose mothers had acute toxoplasmosis in the course of pregnancy; therefore, these children must be subjected to serological investigation with antibody detection for anti-Toxoplasma gondii (T. gondii).1,2 However, a confirmed serological diagnosis of T. gondii infection through the detection of specific IgM and/or IgA antibodies against the parasite does not occur in all newborns.1,3–5 Therefore, IgG antibodies against T. gondii in serial serum samples must be analyzed and the child remains under outpatient follow-up, which can take months until the definitive diagnosis.1,6